EyePoint Pharmaceuticals (EYPT)
(Real Time Quote from BATS)
$11.20 USD
-0.08 (-0.71%)
Updated Oct 17, 2024 10:32 AM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Brokerage Reports
0 items in cart
EYEPOINT PHARMACEUTICALS, INC. [EYPT]
Reports for Purchase
Showing records 1 - 20 ( 85 total )
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Sustained Release Wet AMD Program Highlighted at RD Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Reiterate Buy; Modulating PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
DAVIO 2 Subgroup Analyses Data in Wet AMD Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Phase 2 DME Trial Starts Patient Dosing; Financing Completed; Reiterate Buy; Adjusting PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Phase 2 Trial in Wet AMD Met All Endpoints; Reiterate Buy; Raising PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for EYPT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
3Q23 Financial Results Reported; Reiterate Buy; Adjusting PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Positive EYP-1901 Masked Safety Data in Two Phase 2 Trials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
DAVIO 2 Trial Reports Positive Interim Masked Safety Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
PAVIA Phase 2 Diabetic Retinopathy Trial Finishes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
YUTIQ Sold for $82.5M Cash Plus Royalties; Reiterate Buy; Raising PT to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Phase 2 DAVIO 2 Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Full-Year 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Collaboration on Long-Acting Complement Inhibitor Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: EYEPOINT PHARMACEUTICALS, INC.
Industry: Medical - Biomedical and Genetics
Preliminary 2022 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y